BMRN - BioMarin Pharmaceutical Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Rafael,
United States
Type: Equity
BMRN price evolution
BMRN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.98 | $972.15 | $747 | $755.13 |
| Short term investments | $252.2 | $299.58 | $318.68 | |
| Net receivables | $777.55 | $691.23 | $637.16 | $633.7 |
| Inventory | $1179.34 | $1183.62 | $1137.98 | $1107.18 |
| Total current assets | $3056.59 | $3259.63 | $2985.01 | $2956.09 |
| Long term investments | $557.08 | $620.55 | $611.13 | |
| Property, plant & equipment | $1045.41 | $1052.9 | $1060.42 | $1066.13 |
| Goodwill & intangible assets | $461.73 | $475.85 | $490.9 | |
| Total noncurrent assets | $3807.49 | $3887.66 | $3885.51 | |
| Total investments | $809.28 | $920.13 | $929.82 | |
| Total assets | $6851.19 | $7067.12 | $6872.67 | $6841.6 |
| Current liabilities | ||||
| Accounts payable | $312.32 | $572.5 | $593.54 | $683.15 |
| Deferred revenue | ||||
| Short long term debt | $494.84 | $494.36 | $493.88 | |
| Total current liabilities | $715.66 | $1067.34 | $1087.9 | $1177.02 |
| Long term debt | $594.63 | $594.12 | $593.61 | $593.1 |
| Total noncurrent liabilities | $713.49 | $710.96 | $713.03 | |
| Total debt | $1088.95 | $1087.96 | $1086.97 | |
| Total liabilities | $1437.8 | $1780.82 | $1798.86 | $1890.05 |
| Shareholders' equity | ||||
| Retained earnings | -$319.64 | -$425.72 | -$532.89 | -$621.55 |
| Other shareholder equity | -$13.17 | $26.8 | -$1.05 | -$28.79 |
| Total shareholder equity | $5286.3 | $5073.82 | $4951.55 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $755.13 | $724.53 | $587.28 | $649.16 |
| Short term investments | $318.68 | $567.01 | $426.6 | $416.23 |
| Net receivables | $633.7 | $461.32 | $373.4 | $448.35 |
| Inventory | $1107.18 | $894.08 | $776.67 | $698.55 |
| Total current assets | $2956.09 | $2751.46 | $2274.39 | $2342.22 |
| Long term investments | $611.13 | $333.83 | $507.79 | $285.47 |
| Property, plant & equipment | $1066.13 | $1114.32 | $1035.46 | $1032.47 |
| Goodwill & intangible assets | $490.9 | $534.77 | $584.85 | $613.47 |
| Total noncurrent assets | $3885.51 | $3623.62 | $3728.94 | $3505.8 |
| Total investments | $929.82 | $900.84 | $934.39 | $701.7 |
| Total assets | $6841.6 | $6375.07 | $6003.32 | $5848.02 |
| Current liabilities | ||||
| Accounts payable | $683.15 | $231.24 | $491.59 | $492.55 |
| Deferred revenue | ||||
| Short long term debt | $493.88 | |||
| Total current liabilities | $1177.02 | $588.88 | $539.82 | $492.55 |
| Long term debt | $593.1 | $1083.2 | $1079.08 | $1075.14 |
| Total noncurrent liabilities | $713.03 | $1183.03 | $1192.76 | $1249.47 |
| Total debt | $1086.97 | $1083.02 | $1079.08 | $1075.14 |
| Total liabilities | $1890.05 | $1771.92 | $1732.59 | $1742.02 |
| Shareholders' equity | ||||
| Retained earnings | -$621.55 | -$789.2 | -$925.69 | -$861.61 |
| Other shareholder equity | -$28.79 | -$0.63 | $14.43 | -$16.14 |
| Total shareholder equity | $4951.55 | $4603.16 | $4270.74 | $4106 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $745.74 | $712.03 | $648.83 | $646.21 |
| Cost of revenue | $130.46 | $125.18 | $135.48 | |
| Gross Profit | $557.28 | $581.57 | $523.65 | $510.73 |
| Operating activities | ||||
| Research & development | $183.79 | $204.99 | $206.25 | |
| Selling, general & administrative | $263.03 | $225.91 | $275.02 | |
| Total operating expenses | $399.87 | $461.12 | $435.19 | $496.51 |
| Operating income | $120.45 | $88.46 | $14.22 | |
| Income from continuing operations | ||||
| EBIT | $135.71 | $109.09 | $25.43 | |
| Income tax expense | $28.36 | $24.96 | $16.89 | -$1.05 |
| Interest expense | $15.09 | $3.57 | $3.55 | $6.1 |
| Net income | ||||
| Net income | $106.08 | $107.17 | $88.66 | $20.38 |
| Income (for common shares) | $107.17 | $88.66 | $20.38 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2419.23 | $2096.04 | $1846.28 | $1860.45 |
| Cost of revenue | $514.85 | $483.67 | $470.51 | $524.27 |
| Gross Profit | $1904.37 | $1612.37 | $1375.76 | $1336.18 |
| Operating activities | ||||
| Research & development | $746.77 | $649.61 | $628.79 | $628.12 |
| Selling, general & administrative | $937.29 | $854.01 | $759.38 | $737.67 |
| Total operating expenses | $1746.28 | $1462.81 | $1458.1 | $1372.95 |
| Operating income | $158.1 | $149.56 | -$82.34 | -$36.77 |
| Income from continuing operations | ||||
| EBIT | $205.9 | $165.55 | -$60.01 | -$13.01 |
| Income tax expense | $20.92 | $8.02 | -$11.27 | -$901.42 |
| Interest expense | $17.34 | $15.97 | $15.34 | $29.31 |
| Net income | ||||
| Net income | $167.65 | $141.56 | -$64.08 | $859.1 |
| Income (for common shares) | $167.65 | $141.56 | -$64.08 | $859.1 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $107.17 | $88.66 | $20.38 | |
| Operating activities | ||||
| Depreciation | $26.46 | $27.35 | $26.86 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $47.91 | $58.25 | $54.85 | |
| Total cash flows from operations | $118.76 | $46.97 | $27.48 | |
| Investing activities | ||||
| Capital expenditures | -$21.33 | -$16.1 | -$28.92 | |
| Investments | $112.32 | $9.87 | -$28.27 | |
| Total cash flows from investing | $60.09 | $90.48 | -$14.24 | -$64.96 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $29.42 | $7.2 | $14.8 | |
| Net borrowings | -$0.02 | -$0.04 | -$0.04 | |
| Total cash flows from financing | -$529.31 | $12.61 | -$42.79 | $10.84 |
| Effect of exchange rate | $2.33 | $3.3 | $1.93 | -$3.65 |
| Change in cash and equivalents | -$79.68 | $225.15 | -$8.13 | -$30.29 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $167.65 | $141.56 | -$64.08 | $859.1 |
| Operating activities | ||||
| Depreciation | $104.39 | $101.97 | $108.04 | $105.17 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $207.1 | $196.31 | $197.26 | $189.71 |
| Total cash flows from operations | $159.26 | $175.9 | $304.54 | $85.36 |
| Investing activities | ||||
| Capital expenditures | -$96.69 | -$17.63 | -$95.58 | -$47.15 |
| Investments | -$3.63 | $8.19 | -$246.09 | $17.46 |
| Total cash flows from investing | -$111.24 | -$20.03 | -$366.31 | -$53.62 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $69.35 | $69.33 | $49.19 | $21.91 |
| Net borrowings | -$2.29 | -$2.6 | -$3.04 | $203.84 |
| Total cash flows from financing | -$18.73 | -$18.65 | -$0.05 | $181.12 |
| Effect of exchange rate | $1.31 | $0.03 | -$0.06 | -$1.15 |
| Change in cash and equivalents | $30.6 | $137.25 | -$61.88 | $211.71 |
News
Fundamentals
| Market cap | $12.51B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 190.55M |
| Revenue | $2.75B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $322.29M |
| Revenue Q/Q | 28.28% |
| Revenue Y/Y | 19.14% |
| P/E ratio | 38.82 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 4.55 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.03 |
| EPS | $1.69 |
|---|---|
| ROA | 4.67% |
| ROE | N/A |
| Debt/Equity | 0.38 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.27 |
| Quick ratio | 2.62 |